Vera Therapeutics, Inc.
VERA
$39.96
-$1.21-2.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 124.17% | 189.44% | 173.23% | 101.16% | 149.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 92.60% | 68.53% | 114.61% | 83.83% | 80.98% |
| Operating Income | -92.60% | -68.53% | -114.61% | -83.83% | -80.98% |
| Income Before Tax | -109.78% | -72.18% | -127.04% | -82.13% | -69.27% |
| Income Tax Expenses | 0.00% | -- | -- | -- | 0.00% |
| Earnings from Continuing Operations | -109.78% | -72.18% | -127.04% | -82.13% | -69.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.78% | -72.18% | -127.04% | -82.13% | -69.27% |
| EBIT | -92.60% | -68.53% | -114.61% | -83.83% | -80.98% |
| EBITDA | -92.54% | -68.36% | -114.38% | -83.62% | -80.80% |
| EPS Basic | -94.00% | -48.06% | -94.79% | -45.82% | -23.98% |
| Normalized Basic EPS | -93.58% | -48.05% | -94.80% | -45.80% | -23.98% |
| EPS Diluted | -94.00% | -48.06% | -94.79% | -45.82% | -23.98% |
| Normalized Diluted EPS | -93.58% | -48.05% | -94.80% | -45.80% | -23.98% |
| Average Basic Shares Outstanding | 8.13% | 16.30% | 16.56% | 24.92% | 36.53% |
| Average Diluted Shares Outstanding | 8.13% | 16.30% | 16.56% | 24.92% | 36.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |